CC
PHAT icon

Centiva Capital’s Phathom Pharmaceuticals PHAT Stock Holding History

Centiva Capital’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,962
Closed -$114K – 2137
2023
Q3 		$114K Buy
+10,962
New +$150K ﹤0.01% 1498

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Centiva Capital's PHAT Position: Q4 2023 in Review

Centiva Capital sold out of Phathom Pharmaceuticals (PHAT) in Q4 2023, closing a stake of 10,962 shares — an estimated $114K sold.

Centiva Capital first reported a position in PHAT in Q3 2023 and held it in 1 quarter. The position peaked at $114K in Q3 2023. 117 funds tracked by Wall St. Rank hold PHAT as of Q4 2023.

  • Centiva Capital reported no remaining Phathom Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Centiva Capital sold 10,962 Phathom Pharmaceuticals shares in Q4 2023, an estimated $114K.
  • Centiva Capital first reported a position in Phathom Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Centiva Capital's Phathom Pharmaceuticals position peaked at $114K in Q3 2023.
  • 117 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2023.

Based on Centiva Capital's 13F filing for Q4 2023, filed 14 Feb 2024.